Top-Rated StocksTop-RatedNASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free CYTK Stock Alerts $59.97 +0.61 (+1.03%) (As of 11:02 AM ET) Add Compare Share Share Today's Range$58.33▼$60.9850-Day Range$57.89▼$75.0552-Week Range$25.98▼$110.25Volume259,474 shsAverage Volume2.70 million shsMarket Capitalization$6.29 billionP/E RatioN/ADividend YieldN/APrice Target$81.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cytokinetics alerts: Email Address Cytokinetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside37.9% Upside$81.60 Price TargetShort InterestBearish13.51% of Float Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.25Based on 46 Articles This WeekInsider TradingSelling Shares$6.32 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.63) to ($4.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.28 out of 5 starsMedical Sector148th out of 928 stocksPharmaceutical Preparations Industry57th out of 431 stocks 4.4 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCytokinetics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cytokinetics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.51% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Cytokinetics has recently decreased by 2.64%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytokinetics has received a 71.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cytokinetics is -0.83. Previous Next 1.8 News and Social Media Coverage News SentimentCytokinetics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 46 news articles for Cytokinetics this week, compared to 7 articles on an average week.Search InterestOnly 5 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,319,540.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Cytokinetics is held by insiders.Read more about Cytokinetics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($4.63) to ($4.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -10.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -10.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cytokinetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingTrump’s Former Wingman Bets Big on AIOne of his AI company’s earliest investors was the CIA’s venture capital arm called In-Q-Tel … named after Q, the fictional character who makes gadgets for James Bond. Soon, an alphabet soup of 30 government agencies would entrust the company with their most sensitive information.Get the full story here. About Cytokinetics Stock (NASDAQ:CYTK)Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Read More CYTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTK Stock News HeadlinesMay 8, 2024 | insidertrades.comFady Ibraham Malik Sells 15,547 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockApril 26, 2024 | insidertrades.comJohn T. Henderson Sells 10,562 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockMay 15 at 7:30 AM | globenewswire.comCytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024May 14 at 6:20 PM | markets.businessinsider.comBuy Rating Justified: Cytokinetics’ Aficamten Shows Superior Efficacy in SEQUOIA-HCM Phase 3 TrialMay 14 at 6:20 PM | markets.businessinsider.comJefferies Keeps Their Buy Rating on Cytokinetics (CYTK)May 14 at 9:34 AM | markets.businessinsider.comBuy Rating Affirmed for Cytokinetics on Aficamten’s Positive Phase 3 Trial OutcomesMay 14 at 4:33 AM | markets.businessinsider.comBuy Rating Affirmed for Cytokinetics on Strong SEQUOIA-HCM Study Results and Favorable Market ProspectsMay 13 at 6:32 PM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Annexon Biosciences (ANNX) and Cytokinetics (CYTK)May 13 at 9:33 AM | globenewswire.comCytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 CongressMay 13 at 9:33 AM | globenewswire.comCytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of MedicineMay 13 at 7:34 AM | americanbankingnews.comJMP Securities Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $106.00May 13 at 7:03 AM | americanbankingnews.comOppenheimer Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $106.00May 13 at 4:44 AM | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Given "Buy" Rating at Needham & Company LLCMay 13 at 2:40 AM | americanbankingnews.comB. Riley Comments on Cytokinetics, Incorporated's Q2 2024 Earnings (NASDAQ:CYTK)May 13 at 2:40 AM | americanbankingnews.comLeerink Partnrs Equities Analysts Reduce Earnings Estimates for Cytokinetics, Incorporated (NASDAQ:CYTK)May 10, 2024 | finance.yahoo.comCytokinetics Inc (CYTK) Reports Q1 2024 Earnings: Widening Losses Amid Expansive Clinical TrialsMay 10, 2024 | finance.yahoo.comCytokinetics First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | markets.businessinsider.comCytokinetics: Buy Rating Affirmed Amid Clinical Advancements and Strategic Regulatory PlansMay 9, 2024 | markets.businessinsider.comCytokinetics: Strong Buy Rating on Promising Aficamten Prospects and Market PotentialMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cytokinetics Amid Promising Phase 3 Trial Results and Strategic FDA EngagementsMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on Cytokinetics’ Aficamten Ahead of Key Phase 3 Study ResultsMay 9, 2024 | markets.businessinsider.comBarclays Keeps Their Buy Rating on Cytokinetics (CYTK)May 9, 2024 | finance.yahoo.comCytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ...May 9, 2024 | finance.yahoo.comCytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call TranscriptMay 8, 2024 | investorplace.comCYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q1 2024See More Headlines Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/15/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTK CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees423Year Founded1997Price Target and Rating Average Stock Price Target$81.60 High Stock Price Target$108.00 Low Stock Price Target$50.00 Potential Upside/Downside+37.5%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($5.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-526,240,000.00 Net Margins-14,141.74% Pretax Margin-14,141.74% Return on EquityN/A Return on Assets-67.32% Debt Debt-to-Equity RatioN/A Current Ratio7.19 Quick Ratio6.12 Sales & Book Value Annual Sales$7.53 million Price / Sales811.96 Cash FlowN/A Price / Cash FlowN/A Book Value($3.94) per share Price / Book-15.07Miscellaneous Outstanding Shares103,000,000Free Float99,503,000Market Cap$6.11 billion OptionableOptionable Beta0.72 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Robert I. Blum (Age 60)CEO, President, Principal Financial Officer & Director Comp: $1.33MMr. Robert C. Wong (Age 56)VP & Chief Accounting Officer Comp: $495.72kDr. Fady Ibraham Malik FACC (Age 60)M.D., Ph.D., Executive Vice President of Research & Development Comp: $839.66kMr. Andrew M. Callos (Age 55)Executive VP & Chief Commercial Officer Comp: $752.84kDr. James A. Spudich Ph.D. (Age 82)Co-Founder & Member of Scientific Advisory Board Comp: $21.94kMr. Jeff LotzVice President of Sales & OperationsMr. Matt YangVice President of Corporate Finance and Financial Planning & AnalysisMr. Steven M. Cook (Age 65)Senior Vice President of Global Supply Chain Operations & Technical Operations Ms. Kari K. Loeser J.D.VP & Chief Compliance OfficerMr. John O. Faurescu Esq.VP, Associate General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsBlueprint MedicinesNASDAQ:BPMCIonis PharmaceuticalsNASDAQ:IONSOrganon & Co.NYSE:OGNBridgeBio PharmaNASDAQ:BBIOIntra-Cellular TherapiesNASDAQ:ITCIView All CompetitorsInsiders & InstitutionsHood River Capital Management LLCBought 135,666 shares on 5/15/2024Ownership: 0.664%Affinity Asset Advisors LLCSold 80,000 shares on 5/15/2024Ownership: 0.078%PEAK6 Investments LLCBought 1,300 shares on 5/15/2024Ownership: 0.000%Gabelli Funds LLCBought 5,000 shares on 5/15/2024Ownership: 0.005%EntryPoint Capital LLCBought 1,050 shares on 5/14/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions CYTK Stock Analysis - Frequently Asked Questions Should I buy or sell Cytokinetics stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CYTK shares. View CYTK analyst ratings or view top-rated stocks. What is Cytokinetics' stock price target for 2024? 15 Wall Street research analysts have issued 12-month price targets for Cytokinetics' stock. Their CYTK share price targets range from $50.00 to $108.00. On average, they expect the company's stock price to reach $81.60 in the next year. This suggests a possible upside of 37.9% from the stock's current price. View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts. How have CYTK shares performed in 2024? Cytokinetics' stock was trading at $83.49 at the beginning of the year. Since then, CYTK stock has decreased by 29.1% and is now trading at $59.19. View the best growth stocks for 2024 here. When is Cytokinetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our CYTK earnings forecast. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) announced its quarterly earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing the consensus estimate of ($1.16) by $0.17. The biopharmaceutical company earned $0.84 million during the quarter, compared to analyst estimates of $0.91 million. The business's revenue was down 81.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.38) EPS. What ETFs hold Cytokinetics' stock? ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS), Fidelity Disruptive Medicine ETF (FMED), Principal Healthcare Innovators ETF (BTEC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), VanEck Biotech ETF (BBH), BNY Mellon Innovators ETF (BKIV) and Harbor Health Care ETF (MEDI). What guidance has Cytokinetics issued on next quarter's earnings? Cytokinetics updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million. What is Robert I. Blum's approval rating as Cytokinetics' CEO? 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). Who are Cytokinetics' major shareholders? Cytokinetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.56%), HAP Trading LLC (0.00%), Westfield Capital Management Co. LP (0.70%), Hood River Capital Management LLC (0.66%), Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. (0.44%) and Principal Financial Group Inc. (0.41%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Santo J Costa and Wendall Wierenga. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTK) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden FINISHED On June 13th?Paradigm PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.